The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin.
 
Yarúa Jaimes
Employment - Boehringer Ingelheim
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Actuate Therapeutics; Agenus; Amgen; AstraZeneca; Atreca; BAKX Therapeutics; Boehringer Ingelheim; Compass Therapeutics; Cullinan Oncology; DAAN Biotherapeutics; EMD Serono; GlaxoSmithKline; I-Mab; ImCheck therapeutics; IQvia; Kineta; Kyowa Kirin International; Mekanistic Therapeutics; Mersana; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Quanta Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Scenic Biotech; Schrodinger; Seagen; Sotio; ST Cube; Stemline Therapeutics; Takeda; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Mrinal M. Gounder
Honoraria - Gerson Lehrman Group; Great Debates and Updates; Guidepoint Global; Med Learning Group; Medscape; MJH/PER; OncLive/MJH Life Sciences; Research to Practice; touchIME
Consulting or Advisory Role - AADi; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Ikena Oncology; Karyopharm Therapeutics; Rain Therapeutics; Regeneron; Springworks Therapeutics; TYME
Research Funding - AADi (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Erasca, Inc (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Ikena Oncology (Inst); Kymera (Inst); Rain Oncology (Inst); Regeneron (Inst); SERVIER (Inst); SpringWorks Therapeutics (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Foundation Medicine
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Epizyme
Research Funding - Advenc; Ascentage Pharma; AstraZeneca/MedImmune (Inst); Cogent Biosciences; Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics
 
Iwona A. Lugowska
Honoraria - Agenus; Amgen; AstraZeneca; BeiGene; BMS; Celon Pharma; Cullinan Oncology; Jacobio; Janssen; Loxo; Macrogenics; Menarini; MSD; Pfizer; Rhizen Pharmaceuticals; ROCHE; Sanofi; Sanofi; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AGENUS (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - BMS
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Alexander Peltzer
Employment - Boehringer Ingelheim
 
Michael Teufel
Employment - Boehringer Ingelheim
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Girish Jayadeva
Employment - Boehringer Ingelheim
 
Patrick Schöffski
Consulting or Advisory Role - Adcendo; Amryt Pharma; Avacta Life Sciences; Boehringer Ingelheim; Boxer Capital; Cogent Biosciences; Curio Science; Deciphera; Eisai; Ellipses Pharma; Exelixis; Genmab; IDRx; LLX Solutions; Medpace; Merck; Moleculin Biotech; NEC OncoImmunity AS; NEC OncoImmunity AS; PharmaMar; Regeneron; Sanofi; SERVIER; Sonata Therapeutics; Studiecentrum voor Kernenergie (SCK CEN); Telix Pharmaceuticals; Transgene; UCB
Research Funding - Adcendo (Inst); CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genmab (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst)